CV Sciences Q2 sales fall on regulatory pressure
CV Sciences Q2 sales fall on regulatory pressure
Overview
U.S. hemp wellness firm's Q2 sales fell 17.5% yr/yr due to restrictive regulations
Company maintained gross margin at 48.6% and cut operating expenses by 11.3% yr/yr
Adjusted EBITDA turned negative, reflecting lower sales and gross profit
Outlook
Company says cost actions position it to improve profitability and generate positive cash flow as market conditions normalize
CV Sciences remains focused on disciplined capital allocation and operational excellence
Company says results remain pressured by a challenging regulatory and consumer environment
Result Drivers
REGULATORY PRESSURE - Co said lower sales volume was driven by restrictive regulations at the federal level and in certain states
NEW PRODUCT CONTRIBUTION - Co said 44% of Q2 net revenue came from products launched since Jan. 1, 2023
LOWER AVERAGE PRICES - Co said it realized some minor decreases in average sales prices
Company press release: ID:nACSJLpkCa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| $2.99 mln |
|
Q2 Net Loss |
| $775,000 |
|
Q2 Gross Profit |
| $1.45 mln |
|
Q2 Operating Expenses |
| $1.75 mln |
|
Q2 Operating Income |
| -$301,000 |
|
Q2 Pretax Loss |
| $770,000 |
|
Reuters Recommended Reads
Aug 13 - Charlotte's Web Q2 revenue falls as retail exits weigh
Aug 12 - Planet 13 Q2 revenue falls on California retail exit, price pressure
Aug 13 - Artelo Biosciences Q2 net loss narrows as R&D expenses fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)